Raymond James Financial Inc. Buys New Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Raymond James Financial Inc. bought a new position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 10,670 shares of the biotechnology company’s stock, valued at approximately $80,000.

A number of other hedge funds have also added to or reduced their stakes in the business. Venturi Wealth Management LLC bought a new position in BioCryst Pharmaceuticals in the fourth quarter worth approximately $46,000. R Squared Ltd acquired a new position in shares of BioCryst Pharmaceuticals during the fourth quarter worth approximately $48,000. KBC Group NV lifted its holdings in shares of BioCryst Pharmaceuticals by 80.1% in the 4th quarter. KBC Group NV now owns 10,198 shares of the biotechnology company’s stock worth $77,000 after purchasing an additional 4,537 shares in the last quarter. Choreo LLC bought a new position in shares of BioCryst Pharmaceuticals in the 4th quarter worth $106,000. Finally, Xponance Inc. grew its position in BioCryst Pharmaceuticals by 9.1% in the 4th quarter. Xponance Inc. now owns 14,896 shares of the biotechnology company’s stock valued at $112,000 after purchasing an additional 1,242 shares during the period. 85.88% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several brokerages recently issued reports on BCRX. JPMorgan Chase & Co. lifted their target price on BioCryst Pharmaceuticals from $10.00 to $13.00 and gave the company an “overweight” rating in a research report on Tuesday, May 6th. Cantor Fitzgerald began coverage on shares of BioCryst Pharmaceuticals in a report on Tuesday, April 29th. They set an “overweight” rating and a $20.00 price objective on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Tuesday, May 6th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $13.00 target price (up from $11.00) on shares of BioCryst Pharmaceuticals in a research report on Tuesday, May 6th. Finally, StockNews.com raised shares of BioCryst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Tuesday, May 6th. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $16.56.

BioCryst Pharmaceuticals Trading Down 2.7%

BCRX stock opened at $10.06 on Wednesday. The stock’s 50 day simple moving average is $7.96 and its 200 day simple moving average is $7.92. BioCryst Pharmaceuticals, Inc. has a 12-month low of $5.35 and a 12-month high of $11.11. The stock has a market capitalization of $2.11 billion, a PE ratio of -16.49 and a beta of 1.08.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings results on Monday, February 24th. The biotechnology company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.06). The firm had revenue of $131.50 million for the quarter, compared to analysts’ expectations of $126.64 million. The firm’s revenue for the quarter was up 40.8% on a year-over-year basis. During the same period in the previous year, the company earned $0.28 EPS. On average, research analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current year.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.